Bristol-Myers Squibb Company
BMY
$59.01
-$1.27-2.11%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
--
EPS (TTM)
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 12.34B | 11.89B | 12.20B | 11.87B | 11.48B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.34B | 11.89B | 12.20B | 11.87B | 11.48B |
| Cost of Revenue | 3.21B | 2.86B | 2.97B | 2.91B | 2.71B |
| Gross Profit | 9.13B | 9.04B | 9.23B | 8.96B | 8.77B |
| SG&A Expenses | 1.85B | 2.08B | 1.92B | 1.97B | 2.06B |
| Depreciation & Amortization | 1.69B | 2.41B | 2.42B | 2.36B | 2.28B |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.55B | 9.70B | 9.60B | 9.58B | 9.53B |
| Operating Income | 2.80B | 2.20B | 2.60B | 2.28B | 1.95B |
| Income Before Tax | 175.00M | 1.68B | 1.29B | -11.52B | 1.67B |
| Income Tax Expenses | 99.00M | 461.00M | -398.00M | 392.00M | -88.00M |
| Earnings from Continuing Operations | 76.00M | 1.22B | 1.68B | -11.91B | 1.76B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -4.00M | -4.00M | -4.00M | -3.00M | 0.00 |
| Net Income | 72.00M | 1.21B | 1.68B | -11.91B | 1.76B |
| EBIT | 2.80B | 2.20B | 2.60B | 2.28B | 1.95B |
| EBITDA | 4.65B | 4.83B | 5.22B | 4.75B | 4.40B |
| EPS Basic | 0.04 | 0.60 | 0.83 | -5.89 | 0.87 |
| Normalized Basic EPS | 0.76 | 0.72 | 0.82 | 0.76 | 0.73 |
| EPS Diluted | 0.04 | 0.60 | 0.83 | -5.89 | 0.87 |
| Normalized Diluted EPS | 0.75 | 0.72 | 0.82 | 0.76 | 0.73 |
| Average Basic Shares Outstanding | 2.03B | 2.03B | 2.03B | 2.02B | 2.03B |
| Average Diluted Shares Outstanding | 2.04B | 2.03B | 2.03B | 2.02B | 2.03B |
| Dividend Per Share | 0.62 | 0.60 | 0.60 | 0.60 | 0.60 |
| Payout Ratio | 1,691.67% | 100.41% | 72.44% | -10.18% | 65.83% |
